Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Thailand
UK
Ukraine
Orion will publish its Interim Report January-June 2010 on Tuesday, 10 August 2010 approximately at 12:00 Finnish time (EEST). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en promptly after the publishing.
News conference for analysts and media on Tuesday 10 August 2010 at 14:30 EEST
A news conference for analysts and media on the Q2 result will be held on Tuesday 10 August 2010 at 14:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review.
Live webcast and conference call
The event can be followed live as a webcast accessible at www.orion.fi/en. Questions can be asked also through conference call lines after the result presentation.
The conference call ID is 869,772 and the phone numbers to participate the conference are:
when calling from the United States +1 334 323 6203
when calling from other countries +44 (0)20 7162 0125
News conference recordings
A recording of the event in English will be available later the same day via a link on the Orion website. A recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.
Silent period
The silent period preceding the publication of the Q2 report is ongoing and continues until the disclosure.
Orion Corporation
| Timo Lappalainen President and CEO | Jari Karlson CFO |
Publisher:
Orion Corporation
www.orion.fi/en
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.